Synairgen skyrockets as SNG001 shows impact in COVID-19

20 July 2020
stock-market-big

Shares in Synairgen (LSE: SNG) closed more than 400% higher on Monday.

The UK-based respiratory drug discovery and development company had that morning announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalized COVID-19 patients.

Those who received SNG001 had a 79% lower risk of developing severe disease compared to placebo, and were more than twice as likely to recover from COVID-19.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology